Trial · NCT05087771
In Hospital IM Naltrexone: A Pilot Study
NCT05087771, Phase 4, Withdrawn, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. In Hospital IM Naltrexone: A Pilot Study. Trials, record NCT05087771. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05087771
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- In Hospital IM Naltrexone: A Pilot Study
- NCT number
- NCT05087771
- Status
- Withdrawn
- Phases
- Phase 4
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Alcohol Use Disorder
- Interventions
- injectable naltrexone, oral naltrexone
- First posted
- 2021-10-21
- Last updated
- 2023-04-07
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment rate | 12 months | The investigators will assess recruitment rate for IM naltrexone and oral naltrexone o Recruitment is defined as (\[number of participants enrolled / number of participants enrolled approached\] / 12 months) |
| Secondary | II. Acceptability and Feasibility Measures | prior to study implementation and after 50% enrollment is completed, approximately 6 months from study start date | The investigators will use survey questions to assess acceptability and feasibility with responses measured using a 5-point Likert scale titled "Intervention Acceptability and Feasibility". The scale ranges include: (1) completely disagree \[minimum value\], (2) disagree, (3) neither agree nor disagree, (4) agree, (5) completely agrees \[maximum value\]). Maximum value (5) means the intervention is the most acceptable and the most feasible. |
| Secondary | III. Comparative Effectiveness: Combined all-cause 30-day readmission rate + all cause 30-day emergency department encounter rate. | 30 days from time of last person enrolled in study | Combined all-cause 30-day readmission rate + all cause 30-day emergency department encounter rate Data assessing measures III and IV will be obtained from Health Data Compass at University of Colorado27 which includes data obtained from the All Payer Claims Dataset (APCD)28 and University of Colorado health related-encounters. |
| Secondary | IV. Comparative Effectiveness: 90-day addiction treatment encounter rate for participants randomized to IM vs. oral naltrexone | 90 days from time of last person enrolled in study | 90-day addiction treatment encounter rate for participants randomized to IM vs. oral naltrexone defined as "documentation of ≥ 1 healthcare encounters with an associated International Statistical Classification of Diseases and Related Health Problems (ICD)-code for alcohol use disorder (F10.X) identified within 90 days following the index hospitalization" o Data assessing measures III and IV will be obtained from Health Data Compass at University of Colorado27 which includes data obtained from the All Payer Claims Dataset (APCD)28 and UCHealth related-encounters. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05087771
GET https://conductscience.org/api/trials/v1/NCT05087771/papers?page=2